 |
|
|
| |
Simeprevir Overview: From IFN-Containing to IFN-Free Regimens
|
| |
| |
Reported by Jules Levin
HEP DART 2013, December 8-12, 2013, Big Island, HI, USA
AASLD: SVR results of a once-daily regimen of simeprevir (SMV, TMC435) plus sofosbuvir (SOF, GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naïve and prior null responder patients: The COSMOS study - (11/05/13)
An all-oral phase IIa study combining Simeprevir, TMC647055 and JNJ56914845 in hepatitis C patients to be initiated - (12/16/13)
AASLD: Summary from AASLD 2013 for Hepatitis C Washington 1-5 November 2013 - Written by Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany - (12/02/13)
AASLD: Janssen at AASLD - (11/18/13)
64rd Annual Meeting of the American Association for the Study of Liver Diseases Washington, DC Nov 1-5 2013
Simeprevir (Olysio) J & J Patient Access Programs
Sofosbuvir (Sovaldi) - Gilead U.S. Patient Assistance Program
Gaston Picchio
Janssen Research & Development LLC,
Titusville, NJ, USA
Simeprevir+Sofosbuvir COSMOS Results below
|
| |
|
|
|
|
|
